We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

126 hedge funds and large institutions have $116M invested in iShares US Pharmaceuticals ETF in 2023 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 33 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

7% more funds holding

Funds holding: 118 → 126 (+8)

0.93% more ownership

Funds ownership: 32.26% → 33.19% (+0.93%)

32% less capital inflows, than outflows

Capital inflows: $11.9M | Capital outflows: $17.5M

55% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 33

Holders
126
Holders Change
+8
Holders Change %
+6.78%
% of All Funds
2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
15
Reduced
33
Closed
6
Calls
$320​K
Puts
–
Net Calls
+$320​K
Net Calls Change
-⁠$92​K

IHE Hedge Fund Activity: Q3 2023 in Review

126 of the 6,315 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2023, worth a combined $116M — down 4.5% from $121M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new IHE positions and 6 closed out — a net gain of 6 holders — while 15 added to existing stakes and 33 trimmed.

The largest buyer was Envestnet Asset Management, adding an estimated $6.78M. The largest seller was Susquehanna International Group, cutting an estimated $4.66M.

  • 126 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2023, up from 118 in Q2 2023.
  • Funds reported $116M of iShares US Pharmaceuticals ETF stock for Q3 2023, down 4.5% quarter-over-quarter.
  • 12 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2023 and 6 closed out, a net change of +6 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2023 was Envestnet Asset Management, an estimated $6.78M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2023 was Susquehanna International Group, an estimated $4.66M sold.

Based on aggregated 13F filings for Q3 2023.